scholarly journals Clinicopathlogic and Immunohistochemical Characteristics of Triple Negative Invasive Lobular Carcinoma

2011 ◽  
Vol 52 (1) ◽  
pp. 89 ◽  
Author(s):  
Ja Seung Koo ◽  
WooHee Jung
Keyword(s):  
Invasive Lobular Carcinoma ◽  
Triple Negative ◽  
Lobular Carcinoma

scholarly journals Triple negative invasive lobular carcinoma of the breast presents as small bowel obstruction

2017 ◽  
Vol 37 ◽  
pp. 79-82
Author(s):  
Mariya Khokhlova ◽  
Heidi Roppelt ◽  
Bradley Gluck ◽  
Jingxuan Liu ◽  
Kester Haye ◽  
...  
Keyword(s):  
Small Bowel ◽  
Small Bowel Obstruction ◽  
Bowel Obstruction ◽  
Invasive Lobular Carcinoma ◽  
Triple Negative ◽  
Lobular Carcinoma ◽  
Carcinoma Of The Breast

scholarly journals Gastric Metastasis of Triple Negative Invasive Lobular Carcinoma

Rare Tumors ◽  
2015 ◽  
Vol 7 (2) ◽  
pp. 57-59 ◽  
Author(s):  
Caglayan Geredeli ◽  
Osman Dogru ◽  
Ethem Omeroglu ◽  
Farise Yilmaz ◽  
Faruk Cicekci
Keyword(s):  
Invasive Lobular Carcinoma ◽  
Triple Negative ◽  
Lobular Carcinoma ◽  
Gastric Metastasis

Correlation of Clinicopathologic Parameters and Immunohistochemical Features of Triple-negative Invasive Lobular Carcinoma

2014 ◽  
Vol 22 (6) ◽  
pp. e18-e26 ◽  
Author(s):  
Aparna Harbhajanka ◽  
Ihab Lamzabi ◽  
Rohit I. Singh ◽  
Ritu Ghai ◽  
Vijaya B. Reddy ◽  
...  
Keyword(s):  
Invasive Lobular Carcinoma ◽  
Triple Negative ◽  
Lobular Carcinoma ◽  
Clinicopathologic Parameters

scholarly journals Molecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report

2019 ◽  
Vol 7 (3) ◽  
pp. 442-444 ◽  
Author(s):  
Naziya Samreen ◽  
Katie N. Hunt ◽  
Carrie B. Hruska ◽  
Deborah J. Rhodes
Keyword(s):  
Case Report ◽  
Invasive Lobular Carcinoma ◽  
Breast Imaging ◽  
Lobular Carcinoma ◽  
Molecular Breast Imaging ◽  
Dense Breasts

Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI

2021 ◽  
Author(s):  
Su Min Ha ◽  
Jung Min Chang ◽  
Soo-Yeon Kim ◽  
Su Hyun Lee ◽  
Eun Sil Kim ◽  
...  
Keyword(s):  
Invasive Lobular Carcinoma ◽  
Lobular Carcinoma ◽  
Nodal Burden

scholarly journals E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Eike Burandt ◽  
Felix Lübbersmeyer ◽  
Natalia Gorbokon ◽  
Franziska Büscheck ◽  
Andreas M. Luebke ◽  
...  
Keyword(s):  
Tissue Microarray ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Lobular Carcinoma ◽  
Tumor Stage ◽  
Advanced Tumor Stage ◽  
Carcinoma Of The Breast ◽  
Advanced Tumor ◽  
Tumor Entities ◽  
E Cadherin

Abstract Background The E-Cadherin gene (CDH1, Cadherin 1), located at 16q22.1 encodes for a calcium-dependent membranous glycoprotein with an important role in cellular adhesion and polarity maintenance. Methods To systematically determine E-Cadherin protein expression in normal and cancerous tissues, 14,637 tumor samples from 112 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. Results E-Cadherin was strongly expressed in normal epithelial cells of most organs. From 77 tumor entities derived from cell types normally positive for E-Cadherin, 35 (45.5%) retained at least a weak E-Cadherin immunostaining in ≥99% of cases and 61 (79.2%) in ≥90% of cases. Tumors with the highest rates of E-Cadherin loss included Merkel cell carcinoma, anaplastic thyroid carcinoma, lobular carcinoma of the breast, and sarcomatoid and small cell neuroendocrine carcinomas of the urinary bladder. Reduced E-Cadherin expression was linked to higher grade (p = 0.0009), triple negative receptor status (p = 0.0336), and poor prognosis (p = 0.0466) in invasive breast carcinoma of no special type, triple negative receptor status in lobular carcinoma of the breast (p = 0.0454), advanced pT stage (p = 0.0047) and lymph node metastasis in colorectal cancer (p < 0.0001), and was more common in recurrent than in primary prostate cancer (p < 0.0001). Of 29 tumor entities derived from E-Cadherin negative normal tissues, a weak to strong E-Cadherin staining could be detected in at least 10% of cases in 15 different tumor entities (51.7%). Tumors with the highest frequency of E-Cadherin upregulation included various subtypes of testicular germ cell tumors and renal cell carcinomas (RCC). E-Cadherin upregulation was more commonly seen in malignant than in benign soft tissue tumors (p = 0.0104) and was associated with advanced tumor stage (p = 0.0276) and higher grade (p = 0.0035) in clear cell RCC, and linked to advanced tumor stage (p = 0.0424) and poor prognosis in papillary RCC (p ≤ 0.05). Conclusion E-Cadherin is consistently expressed in various epithelial cancers. Down-regulation or loss of E-Cadherin expression in cancers arising from E-Cadherin positive tissues as well as E-Cadherin neo-expression in cancers arising from E-Cadherin negative tissues is linked to cancer progression and may reflect tumor dedifferentiation.

Sign in / Sign up

Export Citation Format

Share Document